System-IGF-1 Pathway and Alzheimer's Disease (SIGAL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00647478|
Recruitment Status : Completed
First Posted : March 31, 2008
Last Update Posted : May 1, 2018
|Condition or disease|
|Alzheimer's Disease Mild Cognitive Impairment Cognitive Function 1, Social Control With Normal Activities of Daily Living|
AD is the most common cause of dementia. During aging, decline of biological brain functions due to a number of genetic and environmental factors facilitates the onset of AD. MCI includes prodromal AD.
The identification of the risk factors for AD must be a priority in order to define the best therapeutic approach.
Recent data support the notion that IGF-I pathway accounts for neuronal protection, with a dual effect, on both brain Aβ peptide and tau protein.
This large, multicenter, prospective, observational, cross-sectional population-based study in 3 parallel groups (200 participants per group) is aimed to assess differences between IGF-I and IGFBP3 circulating levels and polymorphisms in AD patients and control elderly subjects, and in MCI patients.
|Study Type :||Observational|
|Actual Enrollment :||693 participants|
|Official Title:||A Multicenter Study to Assess Differences Between Circulating Levels of IGF-I and IGFBP-3 in Patients With Sporadic Late-onset Alzheimer's Disease and Control Elderly Subjects.|
|Study Start Date :||October 2007|
|Actual Primary Completion Date :||October 2010|
|Actual Study Completion Date :||July 2012|
Control elderly subjects with normal cognitive function
- Circulating IGF-I and IGFBP-3 levels in AD patients and control elderly subjects at the time of assessment(T0). [ Time Frame: 24 hours ]
- Circulating IGF-I and IGFBP-3 levels [ Time Frame: 24 hours ]
- Genetic polymorphisms in IGF-I / IGFBP-3 [ Time Frame: 24 hours ]
- Circulating IGF-I and IGFBP-3 levels and genetic polymorphisms in IGF-I / IGFBP-3 according to cognitive function. [ Time Frame: 24 hours ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00647478
|Broca Hospital Memory Clinic (CMRR)|
|Paris, France, 75013|
|Principal Investigator:||Olivier Hanon, MD, PhD||Assistance Publique - Hôpitaux de Paris|